Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma

Glioblastoma CAR T Cell therapy clinical trials
This is an open, single-arm, dose-escalation and multiple-dose study to evaluate the safety, tolerability and preliminary effectiveness of B7-H3-targeting Chimeric Antigen Receptor-T (CAR-T) cell therapy on patients with recurrent glioblastomas. The study also plan to explore the Maximum Tolerated Dose (MTD) and determine the Recommended Phase II Dose (RP2D) of the CAR-T cell therapy.

Share This Post

March 2023:

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Sequential Assignment
Intervention Model Description: a “3+3” design is used to determine Maximum Tolerated Dose (MTD) and the recommended phase 2 dose (RP2D)
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open, Single-arm, Phase 1 Study to Evaluate the Safety/Preliminary Effectiveness and Determine the Maximal Tolerated Dose of B7-H3-targeting CAR-T Cell Therapy in Treating Recurrent Glioblastomas
Actual Study Start Date : January 27, 2022
Estimated Primary Completion Date : December 31, 2024
Estimated Study Completion Date : December 31, 2024

Dose-escalation phase:

A “3+3” dose-escalation design is used to determine MTD & R2PD. Anti-B7-H3 autologous CAR-T cells were given biweekly to patients at the following doses for each cycle, and 4 cycles as one course. Dose 1: 3 patients at a dose of 20 million cells for each cycle. Dose 2: 3 patients at a dose of 60 million cells for each cycle. Dose 3: 3 patients at a dose of 150 million cells for each cycle. Dose 4: 3 patients at a dose of 450 million cells for each cycle. Dose 5: 3 patients at a dose of 900 million cells for each cycle.

R2PD confirmation phase:

Determine the R2PD based on the results from the previous dose-escalation study; Treat another 12 patients with anti-B7-H3 autologous CAR-T cells biweekly at the R2PD to further confirm the safety of R2PD.

At each dose phase, if the patients show tolerance and response to the treatment, these patients would receive several courses of treatment at the PI’s discretion.


Inclusion criteria

  1. Male or female, aged 18-75 years (including 18 and 75 years old)
  2. Patients with relapsed glioblastoma, as confirmed by positron emission tomography (PET) or histologic pathology
  3. A >= 30% staining extent of B7-H3 in his/her primary/recurrent tumor tissue by the immunochemical method;
  4. Karnofsky scale score >=50
  5. Availability in collecting peripheral blood mononuclear cells (PBMCs)
  6. Adequate laboratory values and adequate organ function;
  7. Patients with childbearing/fathering potential must agree to use highly effective contraception.

Exclusion criteria

  1. Pregnant or breastfeeding females
  2. Contraindication to bevacizumab
  3. Within 5 days before the CAR-T cell infusion, subjects receiving systemic administration of steroids with dosage greater than 10mg/d prednisone or the equivalent doses of other steroids ( not including inhaled corticosteroid)
  4. Comorbid with Other uncontrolled malignancies
  5. Active immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus or tuberculosis infection;
  6. Subjects receiving the placement of a carmustine slow-release wafer within 6 months before the enrollment;
  7. Autoimmune diseases;
  8. Receiving long-term immunosuppressive treatment after organ transplantation;
  9. Severe or uncontrolled psychiatric diseases or condition that could increase adverse events or interfere the evaluation of outcomes;
  10. Not recovered from the toxicities or side effects by previous treatment;
  11. Subjects who have participated in the other interventional trial within one month before enrollment, or have received other CAR-T cell therapies or gene-modified cell therapy before enrollment.
  12. Subjects with medical conditions that affect signing the written informed consent or complying with the research procedures, including, but not limited to, cardio-cerebral vascular diseases, renal dysfunction/failure, pulmonary embolism, coagulation disorders, active systemic infection, uncontrolled infection, et. al., or patients who are unwilling or unable to comply with the research procedures;
  13. Subjects with other conditions that would interfere with trial participation at the investigator’s discretion.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy